e3 ligase cbl-b tam receptors regulate cancer metastasis via natural killer cells
tumour metastasis primary cause mortality cancer patients remains key challenge cancer therapy new therapeutic approaches block inhibitory pathways immune system renewed hopes utility therapies show genetic deletion e3 ubiquitin ligase cbl-b casitas b-lineage lymphoma-b targeted inactivation e3 ligase activity licenses natural killer nk cells spontaneously reject metastatic tumours tam tyrosine kinase receptors tyro3 axl mer also known mertk identified ubiquitylation substrates cbl-b treatment wild-type nk cells newly developed small molecule tam kinase inhibitor conferred therapeutic potential efficiently enhancing anti-metastatic nk cell activity vivo oral intraperitoneal administration using tam inhibitor markedly reduced murine mammary cancer melanoma metastases dependent nk cells report anticoagulant warfarin exerts anti-metastatic activity mice via cbl-b/tam receptors nk cells providing molecular explanation year-old puzzle cancer biology novel tam/cbl-b inhibitory pathway shows might possible develop pill awakens innate immune system kill cancer metastases
